Humanin

Humanin is a 24-amino-acid peptide encoded in mitochondrial DNA. It was discovered in 2001 as the first mitochondrial-derived peptide (MDP) and has shown neuroprotective, anti-apoptotic, and metabolic regulatory properties in laboratory and animal research.

Humanin is available as a research peptide but is not FDA-approved for any indication. There are no standardized supplements or pharmaceutical formulations. Some longevity-focused researchers are studying it, but clinical use is entirely experimental.

Circulating humanin levels decline with age. Studies of centenarians show they maintain higher humanin levels than age-matched controls, suggesting it may play a role in longevity. The decline in humanin production as mitochondrial function decreases with age is an active area of aging research.

Humanin was originally discovered through its ability to protect brain cells from amyloid-beta toxicity, the protein associated with Alzheimer disease. Animal studies show neuroprotective effects, but no human clinical trials for Alzheimer have been completed.

Both are mitochondrial-derived peptides (MDPs) encoded in mitochondrial DNA. Humanin is primarily neuroprotective and anti-apoptotic, while MOTS-c primarily targets metabolic regulation and exercise mimicry. They work through different receptor systems but both decline with age.

Animal studies demonstrate that humanin treatment improves insulin sensitivity in high-fat diet models through STAT3 signaling in skeletal muscle. Human data is limited to observational studies showing lower humanin levels correlate with metabolic disease markers.

There is very limited human safety data for exogenous humanin administration. It is an endogenous peptide (your body produces it naturally), which is generally favorable for safety, but the effects of supplementation at pharmacological doses are not well characterized.

HNG is a synthetic analog of humanin where the serine at position 14 is replaced with glycine. This modification makes it approximately 1000 times more potent than native humanin in cell culture studies. Most animal research uses HNG rather than native humanin.

Animal studies have used intranasal, subcutaneous, intraperitoneal, and intracerebroventricular administration routes. No standardized human dosing protocol exists. The intranasal route has shown promise for brain delivery in animal models.

Besides humanin, known MDPs include MOTS-c (metabolic regulator), SHLPs 1-6 (small humanin-like peptides), and others being discovered. This is a rapidly expanding field, with new MDPs identified regularly as researchers explore the mitochondrial genome.

Yes. Humanin binds to IGFBP-3, a protein that normally inhibits IGF-1 signaling. By binding IGFBP-3, humanin may modulate IGF-1 availability. This interaction is complex and context-dependent, with implications for both longevity and cancer biology research.

Current research directions include Alzheimer disease clinical trials, metabolic disease applications, cardiovascular protection, and understanding the MDP family. The relationship between declining humanin levels and age-related diseases is a particularly active area of investigation.